Nuwellis (NUWE) announced that the United States Patent and Trademark Office recently issued a new U.S. patent covering advanced safety mechanisms for blood return line clamps used in extracorporeal blood filtration systems. The issued patent corresponds to U.S. Patent Application No. 18/298,810 and is assigned to Nuwellis. The newly issued patent protects safety-focused design innovations intended to improve the reliability and consistency of blood flow control in extracorporeal circuits, with particular relevance for pediatric applications, where precision and safety are critical. These mechanisms are designed to support stable system performance and enhance protection in therapies involving small patient volumes and sensitive extracorporeal conditions.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUWE:
- Nuwellis announces presentation of data on broad utility of Aquadex
- Nuwellis says U.S. children’s hospital initiates Aquadex Ultrafiltration Program
- Nuwellis Reports Q3 2025 Results and Strategic Advances
- Nuwellis reports Q3 EPS 56c
- Nuwellis receives notice of allowance for U.S. patent on Vivian system